B OSTON—X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a biotech company with a market capitalization of $84 million, saw its Chief Medical (TASE:PMCN) Officer Christophe Arbet-Engels recently sell ...

X4 Pharmaceuticals has progressed significantly in its ongoing Phase 3 clinical trial, known as the 4WARD trial, targeting chronic neutropenia, aiming for full enrollment by the end of 2025 and ...

Mav BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that ...

The drug Mavorixafor was previously granted the Fast Track designation for the treatment of WHIM syndrome, a rare immunodeficiency indication for which it received FDA approval in April 2024, X4 said.

B OSTON—Mark Baldry, Chief Commercial Officer of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), recently sold 29,159 shares of the ...

X4 Pharmaceuticals announced the validation of its Marketing Authorization Application (MAA) for mavorixafor, a treatment for WHIM syndrome, by the European Medicines Agency (EMA). This rare ...

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will ...

BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (XFOR) (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit ...

X4 Pharmaceuticals is advancing Mavorixafor, a once-daily oral dose, first in class, small molecule antagonist of the CXCR4 receptor in WHIM syndrome and in chronic neutropenia disorders.

Based on the one-year price targets offered by 6 analysts, the average target price for X4 Pharmaceuticals Inc (NASDAQ:XFOR) is $2.96 with a high estimate of $4.00 and a low estimate of $1.50.

Cambridge, MA — April 24, 2019 — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare ...

X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment ...